Prospects for combined use of oncolytic viruses and CAR T-cells

With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajina, Adam, Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696728/
https://www.ncbi.nlm.nih.gov/pubmed/29157300
http://dx.doi.org/10.1186/s40425-017-0294-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696728/
https://www.ncbi.nlm.nih.gov/pubmed/29157300
http://dx.doi.org/10.1186/s40425-017-0294-6

Ejemplares similares